102 related articles for article (PubMed ID: 2908853)
41. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
42. Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes.
Chiba K; Manabe K; Kobayashi K; Takayama Y; Tani M; Ishizaki T
Eur J Clin Pharmacol; 1993; 44(6):559-62. PubMed ID: 8405013
[TBL] [Abstract][Full Text] [Related]
43. CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
Crespi CL; Chang TK; Waxman DJ
Methods Mol Biol; 2006; 320():115-9. PubMed ID: 16719381
[TBL] [Abstract][Full Text] [Related]
44. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
[TBL] [Abstract][Full Text] [Related]
45. Inhibitors of imipramine metabolism by human liver microsomes.
Skjelbo E; Brøsen K
Br J Clin Pharmacol; 1992 Sep; 34(3):256-61. PubMed ID: 1389950
[TBL] [Abstract][Full Text] [Related]
46. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
47. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.
Baumhäkel M; Kasel D; Rao-Schymanski RA; Böcker R; Beckurts KT; Zaigler M; Barthold D; Fuhr U
Int J Clin Pharmacol Ther; 2001 Dec; 39(12):517-28. PubMed ID: 11770832
[TBL] [Abstract][Full Text] [Related]
48. In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics.
Henthorn TK; Spina E; Dumont E; von Bahr C
Anesthesiology; 1989 Feb; 70(2):339-42. PubMed ID: 2563318
[TBL] [Abstract][Full Text] [Related]
49. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles.
Foti RS; Wahlstrom JL
Drug Metab Dispos; 2008 Mar; 36(3):523-8. PubMed ID: 18048485
[TBL] [Abstract][Full Text] [Related]
50. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
Boobis AR; Seddon CE; Davies DS
Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphism of mephenytoin metabolism.
Inaba T
Prog Clin Biol Res; 1986; 214():139-56. PubMed ID: 3523505
[No Abstract] [Full Text] [Related]
52. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
[TBL] [Abstract][Full Text] [Related]
53. The genetic defect of mephenytoin hydroxylation.
Kalow W
Xenobiotica; 1986 May; 16(5):379-89. PubMed ID: 3739364
[TBL] [Abstract][Full Text] [Related]
54. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450.
Zhao J; Leemann T; Dayer P
Life Sci; 1992; 51(8):575-81. PubMed ID: 1640808
[TBL] [Abstract][Full Text] [Related]
55. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine.
Xu ZH; Xie HG; Zhou HH
Br J Clin Pharmacol; 1996 Oct; 42(4):518-21. PubMed ID: 8904628
[TBL] [Abstract][Full Text] [Related]
56. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
57. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics and polymorphism of human P-450 which activates and detoxicates xenobiotics and carcinogens.
Kato R; Yamazoe Y; Yasumori T
Princess Takamatsu Symp; 1990; 21():45-53. PubMed ID: 2134689
[TBL] [Abstract][Full Text] [Related]
59. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
Fonne-Pfister R; Bargetzi MJ; Meyer UA
Biochem Biophys Res Commun; 1987 Nov; 148(3):1144-50. PubMed ID: 3500719
[TBL] [Abstract][Full Text] [Related]
60. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
